Medication-induced diabetes during induction treatment for ALL, an early marker for future metabolic risk?
| Autor: | Yonatan, Yeshayahu, Dror, Koltin, Jill, Hamilton, Paul C, Nathan, Stacey, Urbach |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Metabolic Syndrome Ontario Pediatric Obesity Waist-Height Ratio Adolescent Remission Induction Induction Chemotherapy Precursor Cell Lymphoblastic Leukemia-Lymphoma Hospitals Pediatric Body Mass Index Risk Factors Obesity Abdominal Antineoplastic Combined Chemotherapy Protocols Glucose Intolerance Diabetes Mellitus Humans Female Survivors Insulin Resistance Child Biomarkers |
| Zdroj: | Pediatric diabetes. 16(2) |
| ISSN: | 1399-5448 |
| Popis: | Medication-induced diabetes (MID) is seen in children treated for acute lymphoblastic leukemia (ALL) mostly during induction, due to the use of l-asparaginase and glucocorticoids. Our objective was to assess whether MID during induction, is a risk factor for future impaired glucose tolerance (IGT), diabetes, or metabolic syndrome. Ninety survivors of pediatric ALL, ages 10 yr and older were recruited, 30 with history of MID and 60 controls. Waist/height ratio0.5 was considered as an increased risk for central adiposity and insulin resistance. Lipid profile and an oral glucose tolerance test (OGTT) were performed. Study patients were older than controls (17.2 vs. 14.9, p0.05). The groups had similar sex distribution, body mass index (BMI) z-score, and Tanner staging. A waist/height ratio of0.5 was seen in 60 and 31.7% of the study and control groups, respectively (p = 0.01). Increased frequency of IGT in the study group compared with the control group was seen (13.3 and 1%, respectively) (p = 0.07). We observed a trend toward higher proportion of patients with multiple features of metabolic syndrome in the study compared with control group (16.7 vs. 5%, p = 0.09). In conclusion, MID during induction may be an early marker for metabolic disturbances later in life. The higher rates of increased waist/height ratio, and subjects with multiple metabolic syndrome features, may predict a metabolic risk in children with history of MID. Rates of IGT were four fold higher in the study group although not statistically significant. MID may be a 'red flag' indicating the need for ongoing metabolic screening and lifestyle modifications to prevent future metabolic disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|